Mirum shares rise after Livmarli meets Phase 3 trial goal

what happened

Shares of Mirum Pharmaceuticals advanced after Livmarli, also known as maralixibat, met the main objective of a recent Phase 3 trial studying treatment for cholestatic pruritus in certain liver-disease patients. Dow Jones Newswires reported that the stock was up 3.3% at $61.05 in Monday’s premarket session. Through Friday’s close, the shares had gained 8.9% year to date.

The trial assessed maralixibat in patients aged six months or older who have ultra-rare cholestatic liver diseases. The company said the treatment produced a statistically significant improvement in pruritus versus placebo among pediatric patients. Serum bile acids fell 70% from baseline with maralixibat, compared with a 3.5% reduction for placebo.

Chief Medical Officer Rob Myers said the two results support the drug’s potential to address pruritus, which he described as a major burden for people with ultra-rare cholestatic liver diseases. Mirum plans to file a supplemental new drug application in the U.S. during the first half of 2027, based on the study findings.

why it matters

The trial outcome gave Mirum shares a near-term lift and sets up a regulatory filing that could expand Livmarli’s use.

instruments